Effects of specific allergen immunotherapy on biological markers and clinical parameters in asthmatic children: a controlled-real life study

Djuric-Filipovic, Ivana; Caminati, Marco; Filipović, Đorđe; Salvottini, Chiara; Živković, Zorica

doi:10.1186/s12948-017-0064-5

Cited by 15 publications

(30 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Measurement of FeNO is a simple and non-invasive assessment of airway inflammation severity in asthmatic patients [16]. It has been used in epidemiological studies of allergic asthma as well as rhinitis [17], and recently it had been used as a supplemental tool for monitoring AIT treatment efficacy in asthmatic children [18]. Within the nasal region, altered nasal NO levels (FnNO) have also been described in a number of conditions, including allergic rhinitis, sinusitis, and nasal polyps [7][8][9].…”

Section: Discussionmentioning

confidence: 99%

“…although AIT with D. pteronyssinus and D. farinae extracts has been found to induce exhaled NO in asthmatic children with mite allergy [19]. However, the results from the previous studies are controversial and a clear demonstration of a reduction in exhaled NO in asthmatic patients taking subcutaneous immunotherapy(SCIT) is lacking [18,20]. According to our data, exhaled NO levels decreased after SCIT with HDM, no matter from the airway reflected by FeNO or from the nose reflected by FnNO.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Fraction exhaled nitric oxide and IOS as potential biomarkers for HDM immunotherapy in patients with allergic rhinitis and asthma

Zhou

et al. 2020

Preprint

View full text Add to dashboard Cite

Background：Allergen specific immunotherapy (AIT) is the only potential disease-modifying treatment of house dust mite (HDM) allergic asthma and rhinitis. The conventional treatment procedure lasted for 3 years, but biomarkers indicating early efficacy from this long-term treatment has not been well illustrated. In this single arm, observation study, we evaluated non-invasive airway inflammation parameters such as Exhaled nitric oxide (FeNO), nasal NO levels (FnNO), and small airway function parameter-impulse oscillometry system (IOS) as well as serum parameters Dermatophagoides pteronyssinus (Derp) specific IgG4 and sIgG4/IgE ratio as potential biomarkers for AIT.Methods：Patients with mild allergic asthma concomitant with allergic rhinitis were treated with subcutaneous immunotherapy of Der p extract. Clinical evaluations including symptom score and medication score, small airway function of spirometer and non-invasive airway inflammation parameters from the nose (FnNO) and lung (FeNO) were collected before and after half year and one year of AIT. Serum Derp specific IgE and IgG4 measurement data were also collected. Results：Symptoms and medication score of patients were alleviated both after half and one-year HDM immunotherapy according to VAS (visual analogue score) and medication score. Improved small airway function (evaluated through IOS) and reduced non-invasive airway allergic inflammation parameters both from the nose (FnNO) and lung (FeNO) were achieved after half and one year AIT. As to serum biomarkers, Der p specific IgG4 increased and Der P specific IgE/IgG4 decreased significantly after one year treatment.Conclusions: One year HDM subcutaneous allergen immunotherapy improved allergic symptoms and reduced medication score in patients with allergic asthma concomitant with rhinitis. Non-invasive airway inflammation parameters such as FeNO and FnNO and small airway function parameter IOS are potential biomarkers for evaluating early efficacy of AIT. Derp specific IgG4 as well as IgE/IgG4 ratio maybe good therapeutic predictors to reflect the efficacy of AIT in the first year of treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Fraction exhaled nitric oxide and IOS as potential biomarkers for HDM immunotherapy in patients with allergic rhinitis and asthma

Zhou

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Measurement of FeNO is a simple and non-invasive assessment of airway in ammation severity in asthmatic patients [16]. It has been used in epidemiological studies of allergic asthma as well as rhinitis [17], and recently it had been used as a supplemental tool for monitoring AIT treatment e cacy in asthmatic children [18]. Within the nasal region, altered nasal NO levels (FnNO) have also been described in a number of conditions, including allergic rhinitis, sinusitis, and nasal polyps [7][8][9].…”

Section: Discussionmentioning

confidence: 99%

Fraction exhaled nitric oxide and IOS as potential biomarkers for HDM immunotherapy in patients with allergic rhinitis and asthma

Zhou

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundAllergen specific immunotherapy (AIT) is the only potential disease-modifying treatment of house dust mite (HDM) allergic asthma and rhinitis. The conventional treatment procedure lasted for 3 years, but biomarkers indicating early efficacy from this long-term treatment has not been well illustrated. In this single arm, observation study, we evaluated non-invasive airway inflammation parameters such as Exhaled nitric oxide (FeNO), nasal NO levels (FnNO), and small airway function parameter-impulse oscillometry system (IOS) as well as serum parameters Dermatophagoides pteronyssinus (Derp) specific IgG4 and sIgG4/IgE ratio as potential biomarkers for AIT.MethodsPatients with mild allergic asthma concomitant with allergic rhinitis were treated with subcutaneous immunotherapy of Der p extract. Clinical evaluations including symptom score and medication score, small airway function of spirometer and non-invasive airway inflammation parameters from the nose (FnNO) and lung (FeNO) were collected before and after half year and one year of AIT. Serum Derp specific IgE and IgG4 measurement data were also collected. ResultsSymptoms and medication score of patients were alleviated both after half and one-year HDM immunotherapy according to VAS (visual analogue score) and medication score. Improved small airway function (evaluated through IOS) and reduced non-invasive airway allergic inflammation parameters both from the nose (FnNO) and lung (FeNO) were achieved after half and one year AIT. As to serum biomarkers, Der p specific IgG4 increased and Der P specific IgE/IgG4 decreased significantly after one year treatment.ConclusionsOne year HDM subcutaneous allergen immunotherapy improved allergic symptoms and reduced medication score in patients with allergic asthma concomitant with rhinitis. Non-invasive airway inflammation parameters such as FeNO and FnNO and small airway function parameter IOS are potential biomarkers for evaluating early efficacy of AIT. Derp specific IgG4 as well as IgE/IgG4 ratio maybe good therapeutic predictors to reflect the efficacy of AIT in the first year of treatment.

show abstract

“…Traditional susceptibility factors are associated with increased risk of adverse effects following inhaled chemical exposures; however, susceptible populations are defined as a result of the average response of the population, which does not imply that all individuals within the population will exhibit exposure effects that are greater, in magnitude or diversity, than their ''healthy'' counterparts. [118][119][120] Furthermore, due to the broad interindividual variability within populations, individuals within the ''healthy'' population often experience effects of a similar magnitude to individuals in ''susceptible'' populations. 6,121 Thus, traditional susceptibility factors alone are not faithful indicators of at-risk individuals.…”

Section: Modeling Interindividual Variability In Pulmonary Diseasementioning

confidence: 99%

Through the Looking Glass: In Vitro Models for Inhalation Toxicology and Interindividual Variability in the Airway

Faber

McCullough

2018

Applied In Vitro Toxicology

View full text Add to dashboard Cite

With 7 million deaths reported annually from air pollution alone, it is evident that adverse effects of inhaled toxicant exposures remain a major public health concern in the 21st century. Assessment and characterization of the impacts of air pollutants on human health stems from epidemiological and clinical studies, which have linked both outdoor and indoor air contaminant exposure to adverse pulmonary and cardiovascular health outcomes. Studies in animal models support epidemiological findings and have been critical in identifying systemic effects of environmental chemicals on cognitive abilities, liver disease, and metabolic dysfunction following inhalation exposure. Likewise, traditional monoculture systems have aided in identifying biomarkers of susceptibility to inhaled toxicants and served as a screening platform for safety assessment of pulmonary toxicants. Despite their contributions, in vivo and classic in vitro models have not been able to accurately represent the heterogeneity of the human population and account for interindividual variability in response to inhaled toxicants and susceptibility to the adverse health effects. Development of new technologies that can investigate genetic predisposition, are cost and time efficient, and are ethically sound, will enhance elucidation of mechanisms of inhalation toxicity, and aid in the development of novel pharmaceuticals and/or safety evaluation. This review will describe the classic and novel cell-based inhalation toxicity models and how these emerging technologies can be incorporated into regulatory or nonregulatory testing to address interindividual variability and improve overall human health.

show abstract

Effects of specific allergen immunotherapy on biological markers and clinical parameters in asthmatic children: a controlled-real life study

Cited by 15 publications

References 38 publications

Fraction exhaled nitric oxide and IOS as potential biomarkers for HDM immunotherapy in patients with allergic rhinitis and asthma

Fraction exhaled nitric oxide and IOS as potential biomarkers for HDM immunotherapy in patients with allergic rhinitis and asthma

Fraction exhaled nitric oxide and IOS as potential biomarkers for HDM immunotherapy in patients with allergic rhinitis and asthma

Through the Looking Glass: In Vitro Models for Inhalation Toxicology and Interindividual Variability in the Airway

Contact Info

Product

Resources

About